A Study of LY2605541 in Healthy Participants and in the Elderly

Healthy Volunteers Clinical Trial

Official title:

Effect of Injection Site on the Pharmacokinetics and Pharmacodynamics of Single Subcutaneous Doses of LY2605541 in Healthy Subjects, and Impact of Body Mass Index and Age on the Pharmacokinetics of LY2605541

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT01818245
• Other study ID #: 12152
• Secondary ID: I2R-MC-BIDF
• Status: Completed
• Phase: Phase 1
• Start date: March 2013
• Est. completion date: July 2013

Study information

• Verified date: March 2018
• Source: Eli Lilly and Company
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This study will include 2 groups (cohorts) of participants:

In Cohort A, this study will look at the amount of LY2605541 that is present in the body after it is injected in 3 different locations in the body of the same participant. At least 16 days will pass between each injection.

In Cohort B, the study will look at how the body absorbs, distributes, and disposes of LY2605541 in participants aged 65 and over.

Participants may enroll in only one cohort.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 52
• Est. completion date: July 2013
• Est. primary completion date: July 2013
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Cohort A: are overtly healthy male or female participants, as determined by medical history and physical examination, aged =18 to =55 years of age

• Cohort B: are male or female elderly (=65 years of age) participants that are overtly healthy, or have stable, chronic medical conditions (including Type 2 Diabetes Mellitus [T2DM]) that, in the investigator's opinion, will not significantly alter the disposition of the drug, will not place the participant at increased risk by participating in the study, and will not interfere with interpretation of the data

• Male participants agree to use a reliable method of birth control during the study and for 3 months following the last dose of the investigational product

• Female participants are women of child-bearing potential who test negative for pregnancy at the time of screening based on a urine pregnancy test and agree to use a reliable method of birth control during the study and for 1 month following the last dose of the investigational product

• Female participants are post-menopausal women, or women not of child-bearing potential due to surgical sterilization (at least 3 months after surgical hysterectomy, or at least 3 months after bilateral oophorectomy or bilateral tubal ligation/occlusion with or without hysterectomy) confirmed by medical history, or menopause

• Have a body mass index (BMI) of 18.5 to 40 kilogram per meter square (kg/m^2), inclusive, at time of admission for Period 1

• Have given written informed consent approved by Lilly and the ethical review board (ERB) governing the site

Exclusion Criteria:

• Are participants that intend to start a change in diet or lose weight during the study; participants will be expected to maintain their approximate current weight throughout the study

• Are excessive smokers (>10 cigarettes per day); participants who smoke =10 cigarettes per day must be able to stop smoking while residing at the clinical research unit (CRU)

Healthy Participants - Cohort A

• Have Type 1 Diabetes Mellitus (T1DM), Type 2 Diabetes Mellitus (T2DM), or a fasting blood glucose (BG) >110 milligrams per deciliter (mg/dL) (6.1 millimoles per liter [mmol/L]) with a glycated hemoglobin (HbA1c) of >6.2%

• Intend to use over-the-counter medication within the 7 days or prescription medication within 14 days prior to dosing (apart from contraceptive medication, vitamin/mineral supplements, occasional paracetamol, thyroxine replacement therapy, and hormone replacement therapy). Antihypertensive and lipid lowering agents are permitted, but must have been administered at stable dose(s) for at least 1 month.

Elderly Participants - Cohort B

• Have T1DM

• Are T2DM participants that require insulin treatment, or have a HbA1c of >10%

• Have started new chronic medication(s) or changed the dose of an existing chronic medication <1 month prior to dosing. Participants are permitted to continue ongoing chronic medications (for example antihypertensive agents, aspirin, non-steroidal anti-inflammatory drugs, lipid lowering agents, thyroxine, hormone replacement therapy, and/or oral anti-diabetic if participants have T2DM). Other stable chronic conditions may be permitted if deemed acceptable by the investigators and Lilly clinical pharmacologist or clinical research physician.

Related Conditions & MeSH terms

• Healthy Volunteers

Intervention

Drug:
• LY2605541

Locations

Country	Name	City	State
United States	For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.	Dallas	Texas

Sponsors (1)

Lead Sponsor	Collaborator
Eli Lilly and Company

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Pharmacokinetics: Area Under the Concentration-Time Curve (AUC): Injection Site (Arm and Thigh) Versus Abdominal Wall Injection (Cohort A)	AUC from time zero to infinity (AUC(0-8)) of LY2605541 was evaluated across injection sites (abdominal wall, arm, and thigh).	Predose and 2, 4, 6, 8, 12, 24, 36, 48, 72, 120, 168, and 216 hours postdose
Primary	Pharmacokinetics: Observed Maximum Plasma Concentration (Cmax): Injection Site (Arm and Thigh) Versus Abdominal Wall Injection (Cohort A)	Cmax of LY2605541 was evaluated across injection sites (abdominal wall, arm, and thigh).	Predose and 2, 4, 6, 8, 12, 24, 36, 48, 72, 120, 168, and 216 hours postdose
Primary	Pharmacokinetics: Area Under the Concentration-Time Curve (AUC): Elderly Participants (=65 Years of Age) Versus Participants =55 Years of Age (Abdominal Injection)	AUC(0-8) for LY2605541 was evaluated.	Predose and 2, 4, 6, 8, 12, 24, 36, 48, 72, 120, 168, and 216 hours postdose
Primary	Pharmacokinetics: Maximum Plasma Concentration (Cmax): Elderly Participants (=65 Years of Age) Versus Participants =55 Years of Age (Abdominal Injection)	Cmax of LY2605541 was evaluated.	Predose and 2, 4, 6, 8, 12, 24, 36, 48, 72, 120, 168, and 216 hours postdose
Secondary	Pharmacodynamics: Total Amount of Glucose Infused (Gtot): Injection Site (Arm and Thigh) Versus Abdominal Wall Injection (Cohort A)	Gtot was evaluated across injection sites (abdominal wall, arm, and thigh).	Predose up to 24 hours post clamp procedure in all treatment periods
Secondary	Pharmacodynamics: Maximum Glucose Infusion Rate (Rmax): Injection Site (Arm and Thigh) Versus Abdominal Wall Injection (Cohort A)	Rmax was evaluated across injection sites (abdominal wall, arm, and thigh).	Predose up to 24 hours post clamp procedure in all treatment periods